Amalgamated Bank’s GT Biopharma GTBP Stock Holding History

Amalgamated Bank’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-99	Closed	-$9K	–	3102
2022 Q1	$9K	Buy	+99	New	+$8.73K	﹤0.01%	2974

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Bank's GTBP Position: Q2 2022 in Review

Amalgamated Bank sold out of GT Biopharma (GTBP) in Q2 2022, closing a stake of 99 shares — an estimated $9K sold.

Amalgamated Bank first reported a position in GTBP in Q1 2022 and held it in 1 quarter. The position peaked at $9K in Q1 2022. 47 funds tracked by Wall St. Rank hold GTBP as of Q2 2022.

Amalgamated Bank reported no remaining GT Biopharma position as of Q2 2022 after selling out during the quarter.
Amalgamated Bank sold 99 GT Biopharma shares in Q2 2022, an estimated $9K.
Amalgamated Bank first reported a position in GT Biopharma in Q1 2022 and held it in 1 quarter.
Amalgamated Bank's GT Biopharma position peaked at $9K in Q1 2022.
47 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.